

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 February 2025 (27.02.2025)



(10) International Publication Number
WO 2025/042872 A1

(51) International Patent Classification:

C07K 16/30 (2006.01) A61P 35/00 (2006.01)
C07K 16/40 (2006.01)

(21) International Application Number:

PCT/US2024/042998

(22) International Filing Date:

20 August 2024 (20.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/533,831 21 August 2023 (21.08.2023) US

(71) Applicants: **AMGEN RESEARCH (MUNICH) GMBH** [DE/DE]; Staffelseestrasse 2, 81477 Munich (DE). **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **STIEGLMAIER, Julia**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **LOLKEMA, Martijn**; c/o Amgen Inc., One Amgen Center Drive, Law Department – Patent Operations M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **MESSMANN, Richard**; c/o Amgen Inc., One Amgen Center Drive, Law Department – Patent Operations M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). **KISCHEL, Roman**; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). **KOUROS-MEHR, Hosein**; c/o Amgen Inc., One Amgen Center Drive, Law Department – Patent Operations M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) Agent: **THOBE, Megan**; One Amgen Center Drive, Law Dept. - Patent Operations, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMBINATION THERAPY FOR TREATING PROSTATE CANCER

(57) Abstract: The present disclosure provides methods of treating prostate cancer patients with an anti-STEAP1 antigen binding protein such as xaluritamig, in combination with lutetium Lu 177 vipivotide tetraxetan.

WO 2025/042872 A1